Key result
Decreased eGFR is linked to higher 24-month cardiovascular mortality in atrial fibrillation.
Why the study?
The study aimed to analyze characteristics of AF patients with CKD from the Croatian cohort of the ESH A Fib survey and determine the association of eGFR with cardiovascular mortality.
Does chronic kidney disease independently increase cardiovascular mortality in patients with atrial fibrillation?
Cohort (n=301)
Yes
Does chronic kidney disease independently increase cardiovascular mortality in patients with atrial fibrillation?
Answers are grounded in this paper and cite their sources.
Chronic kidney disease is highly prevalent among patients with atrial fibrillation and is independently associated with an increased risk of cardiovascular mortality, highlighting the importance of integrated renal and cardiac care.
Our aim was to analyze characteristics of atrial fibrillation (AF) patients with chronic kidney disease (CKD) from the Croatian cohort of the ESH A Fib survey and to determine the association of estimated glomerular filtration rate (eGFR) with cardiovascular (CV) mortality after 24 months of follow-up.Consecutive sample of 301 patients with AF were enrolled in the period 2014 to 2018. Hypertension was defined as BP > 140/90 mm Hg and/or antihypertensive drugs treatment, CKD was defined as eGFR (CKD Epi) < 60 ml/min/1.73 m2 which was confirmed after 3 months.CKD was diagnosed in 45.2% of patients (13.3% in CKD stage > 3b). CKD patients were older than non-CKD and had significantly more frequent coronary heart disease, heart failure and valvular disease. CKD patients had significantly higher CHA2DS2-VASc score and more CKD than non-CKD patients had CHA2DS2-VASc > 2. Crude CV mortality rate per 1000 population at the end of the first year of the follow-up was significantly higher in CKD vs non-CKD group who had shorter mean survival time. CV mortality was independently associated with eGFR, male gender, CHA2DS2VASc and R2CHA2DS2VASc scores.Prevalence of CKD, particularly more advanced stages of CKD, is very high in patients with AF. Observed higher CV mortality and shorter mean survival time in CKD patients could be explained with higher CHA2DS2VASc score which is a consequence of clustering of all score components in CKD patients. However, eGFR was independently associated with CV mortality. In our cohort, R2CHA2DS2VASc score was not associated significantly more with CV mortality than CHA2DS2VASc score.
No takes yet. Share an insight, caveat, or question.
Premužić et al. (2021) conducted a cohort in Atrial Fibrillation with Chronic Kidney Disease (n=301). Chronic kidney disease (decreased eGFR) vs. Normal kidney function (non-CKD) was evaluated on Cardiovascular mortality at 24 months (β=0.169, p=0.04). In patients with atrial fibrillation, decreased eGFR was independently associated with higher cardiovascular mortality over 24 months (β=0.169, p=0.04).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: